Barriers to Universal Availability of Medications for Opioid Use Disorder in US Jails
Hürden für die universelle Verfügbarkeit von Medikamenten zur Behandlung der Opioidgebrauchsstörung in US-Gefängnissen
JAMA Network Open · 16.04.2025 · 8 (4) · e255340
DOI: 10.1001/jamanetworkopen.2025.5340 ↗Auf einen Blick
Eine Querschnittsbefragung von US-Gefängnissen zeigte: Trotz verfügbarer MOUD waren alle 3 Medikamente nur selten gleichzeitig vorhanden. Die Verfügbarkeit hing mit mehreren Kontextfaktoren zusammen.
Fragestellung
Welche MOUD werden in US-Gefängnissen angeboten, welche Faktoren sind mit der Verfügbarkeit verbunden und welche zusätzlichen Unterstützungen werden benötigt?
Methode
Querschnittsbefragung von Gefängnissen zwischen 2. Februar und 1. Juli 2023; Verknüpfung mit öffentlich verfügbaren County-Daten; logistische Regressionen zu Faktoren der Verfügbarkeit.
Ergebnisse
265 US-Gefängnisse mit MOUD-Verfügbarkeit wurden analysiert, gewichtet repräsentativ für 1243 Gefängnisse. Buprenorphin: 812 (65,3 %), Naltrexon: 646 (52,0 %), Methadon: 560 (45,0 %), alle 3: 343 (27,6 %).
Schlussfolgerung der Autor:innen
Die Ergebnisse zeigen, dass Gefängnisse mit MOUD weiter Schwierigkeiten haben, alle 3 Medikamente verfügbar zu machen. Es werden politische, regulatorische, finanzielle, personelle und edukative Lösungen benötigt.
Kernaussagen
- Alle 3 MOUD waren nur in 27,6 % der repräsentativ gewichteten Gefängnisse verfügbar.
- Verfügbarkeit war mit Urbanität, Medicaid-Expansion und County-Faktoren assoziiert.
- Häufige Hürden waren Gefängnispolitik, Abläufe und logistische Zugänglichkeit.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 16.04.2025. Verfasst von Elizabeth Flanagan Balawajder und 7 weiteren Autor:innen. Beteiligte Einrichtung: Public Health Department, NORC at the University of Chicago, Chicago, Illinois. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Health Services Accessibility, Jails, Opiate Substitution Treatment. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Importance Many of the approximately 2 million people being held in US correctional facilities are experiencing an opioid use disorder (OUD). Providing medications for OUD (MOUD) to this population is, therefore, essential to curb the opioid crisis.
Objective
To examine the types of MOUD jails are making available, factors associated with availability, and additional supports needed for jails to address implementation challenges. Design, Setting, and Participants This survey study used a cross-sectional survey of jails conducted between February 2 and July 1, 2023, to explore how they administer MOUD. Publicly available county-level data were connected with the survey responses to assess how variables in the surrounding community were associated with MOUD availability. The survey was administered to jails via mail, telephone, and online survey link. Participants included jails with MOUD available that completed the survey. Exposures Urbanization, average daily population, availability of a health care professional to administer MOUD, whether the state expanded Medicaid, average drive time to MOUD in the county, county overdose rate, and county social vulnerability were assessed. Main Outcomes and Measures The primary outcome was the type of MOUD available in the jail, including buprenorphine, methadone, or naltrexone, or all 3 medications. Binary logistic regressions were conducted to identify the characteristics of jails and county-level factors associated with offering the medications.
Results
A total of 462 jails were invited to complete the survey based on responses to a previous nationally representative survey of jails, in which they indicated that MOUD was available to individuals in their facility. A total of 265 US jails with MOUD available were included in the analysis, representative of 1243 jails nationwide with MOUD available after weighting (812 jails [65.3%] provided buprenorphine, 646 jails [52.0%] provided naltrexone, 560 jails [45.0%] provided methadone, and 343 jails [27.6%] provided all 3 medications). Availability was associated with urbanicity, location in a Medicaid expansion state, county opioid overdose rate, and county social vulnerability. Common challenges included jail policies and procedures and the logistical accessibility of the medication. Conclusions and Relevance The findings of this survey study of US jails demonstrate that jails with MOUD available still experience challenges with making all 3 types of medication available to anyone held within their facility. Policy, regulatory, financing, staffing, and educational solutions are needed to ensure that all detainees with OUD have access to treatment while incarcerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Public Health Department, NORC at the University of Chicago, Chicago, Illinois.
- National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.
- Department of Geography and Geographic Information Science, University of Illinois at Urbana-Champaign, Urbana.
- Office of Research, Baystate Health and University of Massachusetts Chan Medical School-Baystate, Springfield.
- Crown Family School of Social Work, Policy and Practice, University of Chicago, Chicago, Illinois.
- Department of Public Health Sciences, University of Chicago, Chicago, Illinois.
Förderung
- NIDA NIH HHS
Zitieren
APA
Flanagan Balawajder, E., Ducharme, L., Taylor, B. G., Lamuda, P. A., Kolak, M., Friedmann, P. D., Pollack, H. A., & Schneider, J. A. (2025). Barriers to Universal Availability of Medications for Opioid Use Disorder in US Jails. JAMA Network Open, 8(4), e255340. https://doi.org/10.1001/jamanetworkopen.2025.5340
Vancouver
Flanagan Balawajder E, Ducharme L, Taylor BG, Lamuda PA, Kolak M, Friedmann PD, et al. Barriers to Universal Availability of Medications for Opioid Use Disorder in US Jails. JAMA Network Open. 2025;8(4):e255340. doi:10.1001/jamanetworkopen.2025.5340
BibTeX
@article{FlanaganBalawajder2025,
author = {Flanagan Balawajder, Elizabeth and Ducharme, Lori and Taylor, Bruce G and Lamuda, Phoebe A and Kolak, Marynia and Friedmann, Peter D and Pollack, Harold A and Schneider, John A},
title = {Barriers to Universal Availability of Medications for Opioid Use Disorder in US Jails},
journal = {JAMA Network Open},
year = {2025},
volume = {8},
number = {4},
pages = {e255340},
doi = {10.1001/jamanetworkopen.2025.5340}
}
EUVIMED